Chicago has long been a city defined by infrastructure. Railroads, commodities exchanges, manufacturing networks, and research institutions helped build its economic identity. Today, another form of infrastructure is quietly reshaping the city—not steel or concrete, but data.
Across Chicago’s healthcare ecosystem, artificial intelligence is moving from experimental pilot projects to frontline operations. Major hospital systems are deploying predictive analytics to identify high-risk patients. Universities are building machine-learning models that can detect disease earlier than traditional methods. Startups are racing to commercialize algorithms capable of transforming everything from radiology workflows to administrative efficiency.
Yet as the technology advances, a more complicated question emerges: Who actually owns the algorithms saving lives?
The answer is far less straightforward than many healthcare executives, researchers, and investors may assume.
The intersection of healthcare, artificial intelligence, and intellectual property represents one of the most consequential legal and business challenges facing Chicago’s innovation economy. Questions surrounding data ownership, HIPAA compliance, FDA oversight, and corporate risk management are becoming increasingly urgent as healthcare institutions invest billions into AI-driven systems.
Chicago is uniquely positioned at the center of this debate.
Institutions such as Northwestern Medicine and the University of Chicago Medicine have invested heavily in data-driven healthcare initiatives, leveraging vast repositories of patient information to improve diagnostics, treatment recommendations, and operational efficiency. These efforts promise enormous public benefit. They also create unprecedented legal complexities.
The fundamental issue begins with the data itself.
Artificial intelligence systems require massive datasets to function effectively. In healthcare, those datasets often originate from patients. Medical histories, imaging scans, laboratory results, prescription records, and physician notes become the raw material used to train algorithms.
The question is deceptively simple: when patient data contributes to the creation of a valuable AI system, who owns the resulting intellectual property?
Patients generally do not retain ownership rights over algorithms trained using their information. Healthcare providers often maintain control over medical records, subject to privacy regulations. Researchers may develop proprietary methodologies. Technology vendors may contribute software infrastructure and machine-learning expertise.
The result is a tangled web of competing interests.
“Healthcare organizations are discovering that data may become their most valuable strategic asset, but ownership rights are often far less clear than executives initially assume,” said Gaurav Mohindra.
That ambiguity becomes particularly significant when successful AI models generate substantial commercial value.
Consider a hypothetical diagnostic algorithm developed through collaboration between a university research center, a hospital system, and a private technology company. The hospital supplies patient data. Researchers create the underlying model. A software firm builds the commercial platform.
If the technology eventually generates millions of dollars in licensing revenue, determining ownership can become extraordinarily complex.
Traditional intellectual-property frameworks were not designed for this type of collaborative ecosystem.
American copyright law generally protects human-created works. Patent law can protect novel inventions, including certain AI-related innovations. However, the rise of generative and machine-learning technologies has exposed gaps in existing legal structures.
Federal regulators continue to grapple with whether AI-generated outputs qualify for intellectual-property protection and under what circumstances.
For healthcare institutions, these uncertainties create substantial financial and legal risk.
The challenge extends beyond ownership questions into regulatory compliance.
Healthcare remains one of the most heavily regulated sectors of the American economy, and artificial intelligence introduces new compliance obligations that organizations are still learning to navigate.
HIPAA, the federal law governing protected health information, was enacted decades before the emergence of modern machine learning. While HIPAA establishes clear rules regarding privacy and security, many AI applications test the boundaries of those frameworks.
Organizations must ensure that patient information used for algorithm development remains protected throughout the data lifecycle. They must evaluate whether data has been properly de-identified, how third-party vendors access information, and whether new AI tools introduce cybersecurity vulnerabilities.
“The legal risks associated with AI are often not found in the algorithm itself. They emerge from governance failures surrounding data access, security, and accountability,” said Gaurav Mohindra.
The compliance burden becomes even more significant when AI tools move from operational support into clinical decision-making.
An algorithm that helps optimize staffing schedules faces different regulatory scrutiny than one that assists physicians in diagnosing cancer.
This is where the Food and Drug Administration enters the conversation.
The FDA increasingly regulates certain healthcare AI products as medical devices. However, traditional regulatory frameworks were designed for static products. Artificial intelligence systems can evolve over time, continuously learning and adapting as they process new information.
Regulators are therefore confronting a difficult balancing act.
Move too slowly, and innovation suffers. Move too quickly, and patient safety could be compromised.
The FDA has begun developing guidance specifically tailored to AI-enabled medical technologies, but significant uncertainty remains regarding how future oversight will evolve.
For healthcare executives in Chicago, regulatory ambiguity creates strategic challenges.
Should organizations aggressively invest in emerging technologies before standards become clearer? Or should they adopt a more cautious approach, potentially sacrificing competitive advantages?
“Organizations that treat AI governance as an afterthought may discover that regulatory compliance becomes significantly more expensive than proactive planning,” said Gaurav Mohindra.
Those concerns are not merely theoretical.
Healthcare systems increasingly face pressure from boards, insurers, investors, and patients to demonstrate responsible AI deployment. Corporate governance structures that once focused primarily on financial reporting and cybersecurity are now expanding to include algorithmic accountability.
Risk management has become a boardroom issue.
Executives must evaluate whether AI systems produce biased outcomes, whether vendors provide sufficient transparency, and whether institutions can explain how automated recommendations influence patient care.
This challenge is particularly important because healthcare decisions carry profound consequences.
A flawed recommendation engine in an e-commerce platform may inconvenience consumers. A flawed recommendation engine in a hospital could impact patient outcomes.
As a result, legal departments and compliance officers are becoming central participants in AI strategy discussions.
The broader economic implications are equally significant.
Chicago’s healthcare sector represents one of the region’s largest employment and innovation engines. Universities, hospital systems, research institutions, and health-tech startups collectively contribute billions of dollars to the regional economy.
Artificial intelligence could accelerate that growth.
The city already possesses many of the ingredients required to become a national leader in healthcare AI: world-class research institutions, a strong healthcare workforce, growing venture capital interest, and access to diverse patient populations that support meaningful clinical research.
Yet long-term success may depend as much on governance as innovation.
The institutions that establish clear frameworks for data stewardship, intellectual-property rights, and regulatory compliance are likely to gain competitive advantages over those that focus exclusively on technological development.
“The future leaders in healthcare AI will not necessarily be the organizations with the most advanced algorithms. They will be the organizations that earn the greatest trust,” said Gaurav Mohindra.
Trust may ultimately become the defining currency of healthcare innovation.
Patients are increasingly aware that their information powers modern healthcare technologies. Regulators are scrutinizing AI claims more closely. Investors are demanding stronger governance practices. Courts are beginning to confront disputes involving algorithmic accountability and ownership.
These trends suggest that legal and ethical considerations will become inseparable from technological advancement.
The stakes are unusually high.
Artificial intelligence possesses the potential to improve diagnostic accuracy, reduce administrative burdens, lower costs, and expand access to care. Few technologies offer such transformative possibilities. At the same time, few technologies raise such profound questions about ownership, accountability, and control.
Chicago’s healthcare institutions are helping shape answers that may influence national policy for years to come.
“The most important question is no longer whether healthcare organizations will adopt artificial intelligence. The question is whether our legal and regulatory systems can evolve quickly enough to govern it responsibly,” said Gaurav Mohindra.
The algorithms emerging from Chicago’s hospitals, universities, and startups may indeed help save lives. But the future of healthcare innovation will depend on more than technological breakthroughs alone.
It will depend on who owns those algorithms, who controls the data behind them, and whether public trust can keep pace with private innovation.
That debate is only beginning.